Sherman D R, Mdluli K, Hickey M J, Arain T M, Morris S L, Barry C E, Stover C K
Laboratory of Tuberculosis and Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA.
Science. 1996 Jun 14;272(5268):1641-3. doi: 10.1126/science.272.5268.1641.
Mutations that eliminate KatG catalase-peroxidase activity prevent activation of isoniazid and are a major mechanism of resistance to this principal drug for the treatment of Mycobacterium tuberculosis infections. However, the loss of KatG activity in clinical isolates seemed paradoxical because KatG is considered an important factor for the survival of the organism. Expression of either KatG or the recently identified alkyl hydroperoxidase AhpC was sufficient to protect bacilli against the toxic effects of organic peroxides. To survive during infection, isoniazid-resistant KatG mutants have apparently compensated for the loss of KatG catalase-peroxidase activity by a second mutation, resulting in hyperexpression of AhpC.
消除KatG过氧化氢酶-过氧化物酶活性的突变会阻止异烟肼的激活,这是结核分枝杆菌感染主要治疗药物耐药的主要机制。然而,临床分离株中KatG活性的丧失似乎自相矛盾,因为KatG被认为是该生物体生存的一个重要因素。KatG或最近鉴定出的烷基过氧化氢酶AhpC的表达足以保护杆菌免受有机过氧化物的毒性作用。为了在感染期间存活,对异烟肼耐药的KatG突变体显然通过第二次突变弥补了KatG过氧化氢酶-过氧化物酶活性的丧失,导致AhpC的过度表达。